Discovery of potential PD-1 and PD-L1 interaction inhibitors using combined molecular modeling approaches

Öz

Immune checkpoints are regulators of the immune system that maintain immune homeostasis and prevent autoimmunity. Cancer cells often manipulate immune checkpoint mechanisms to escape anti-tumor immune response by overexpressing the immune checkpoint ligands. Thus, the interactions between the immune checkpoint receptors and ligands attracted attention and were proven to be effective targets in treating cancer. In this study, combining several computational approaches, we discovered small molecules that effectively bind to the ligand PD-L1 and have the potential to hamper its interaction with the negative immune checkpoint receptor PD-1. Different pharmacophore models were constructed using triple and quadruple combinations of the interface residues on PD-1, which were used later for scanning the ZINC15 database. 12714 small molecules were retrieved and virtually screened using molecular docking calculations. The complexes of promising small molecules with PD-L1 were further evaluated using energetic and structural analyses. Our results suggest that the three small molecules ZINC21075815, ZINC70692276, and ZINC64031730 retrieved from the ZINC15 database establish stable and energetically favorable interactions with PD-L1 at the hot region consisting of the residues Tyr 56, Glu 58, Arg 113, Met 115 and Tyr 123. These molecules can be used as a starting point to develop more effective and selective anti-PD-1/PD-L1 inhibitors.

Anahtar Kelimeler

• inhibitory T cell receptors
• immunomodulation
• PD-1 Receptor
• drug discovery
• computer-aided drug design
• small molecule libraries
• molecular docking simulations
• molecular dynamic simulations

Kaynakça

1. Wang, X., Teng, F.F., Kong, L., Yu, J.M., PD-L1 expression in human cancers and its association with clinical outcomes, Oncotargets and Therapy, 9, 5023–5039, 2016.
2. Li, Y.C., Zhou, Q., Song, Q.K., Wang, R.B., Lyu, S.Z., Guan, X.D., et al., Overexpression of an Immune Checkpoint (CD155) in Breast Cancer Associated with Prognostic Significance and Exhausted Tumor-Infiltrating Lymphocytes: A Cohort Study, Journal of Immunology Research, 3948928, 2020.
3. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy, Nature Reviews Cancer, 12, 252–264, 2012.
4. Gong, J., Chehrazi-Raffle, A., Reddi, S., Salgia, R., Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations, Journal for Immunotherapy of Cancer, 6, 8, 2018.
5. Darvin, P., Toor, S.M., Nair, V.S., Elkord, E., Immune checkpoint inhibitors: recent progress and potential biomarkers, Experimental and Molecular Medicine, 50, 1–11, 2018.
6. Ai, L., Chen, J., Yan, H., He, Q., Luo, P., Xu, Z., et al., Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy, Drug Design, Development and Therapy, 14, 3625–3649, 2020.
7. Guzik, K., Tomala, M., Muszak, D., Konieczny, M., Hec, A., Blaszkiewicz, U., et al., Development of the Inhibitors That Target the PD-1/PD-L1 Interaction: A Brief Look at Progress on Small Molecules, Peptides and Macrocycles, Molecules, 24, 2071, 2019.
8. Guo, L.B., Wei, R., Lin, Y., Kwok, H.F., Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment-Current Progress, Strategy, and Future Perspective, Frontiers in Immunology, 11, 1508, 2020.

9. Konstantinidou, M., Zarganes-Tzitzikas, T., Magiera-Mularz, K., Holak, T.A., Dömling, A., Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies ?, Angewandte Chemie-International Edition, 57, 4840–4848, 2018.
10. Chames, P., Van Regenmortel, M., Weiss, E., Baty, D., Therapeutic antibodies: successes, limitations and hopes for the future, British Journal of Pharmacology, 157, 220–233, 2009.
11. Ryman, J.T., Meibohm, B., Pharmacokinetics of Monoclonal Antibodies, CPT Pharmacometrics and Systems Pharmacology, 6, 576–588, 2017.
12. Hansel, T.T., Kropshofer, H., Singer, T., Mitchell, J.A., George, A.J.T., The safety and side effects of monoclonal antibodies, Nature Reviews Drug Discovery, 9, 325–338, 2010.
13. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., et al., Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer, New England Journal of Medicine, 366, 2443–2454, 2012.
14. McDermott, J., Jimeno, A., Pembrolizumab: PD-1 Inhibition as a Therapeutic Strategy in Cancer, Drugs of Today, 51, 7–20, 2015.
15. Chen, D.S., Irving, B.A., Hodi, F.S., Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1, Clinical Cancer Research, 18, 6580–6587, 2012.
16. Brahmer, J.R., Tykodi, S.S., Chow, L.Q.M., Hwu, W.J., Topalian, S.L., Hwu, P., et al., Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer, New England Journal of Medicine, 366, 2455–2465, 2012.
17. Yang, J., Riella, L.V., Chock, S., Liu, T., Zhao, X., Yuan, X., et al., The Novel Costimulatory Programmed Death Ligand 1/B7.1 Pathway Is Functional in Inhibiting Alloimmune Responses In Vivo, Journal of Immunology, 187, 1113–1119, 2011.
18. Paterson, A.M., Brown, K.E., Keir, M.E., Vanguri, V.K., Riella, L.V., Chandraker, A., et al., The Programmed Death-1 Ligand 1: B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo, Journal of Immunology, 187, 1097–1105, 2011.
19. Dranitsaris, G., Amir, E., Dorward, K., Biosimilars of Biological Drug Therapies Regulatory, Clinical and Commercial Considerations, Drugs, 71, 1527–1536, 2011.
20. Wells, J.A., McClendon, C.L., Reaching for high-hanging fruit in drug discovery at protein-protein interfaces, Nature, 450, 1001–1009, 2007.
21. Bogan, A.A., Thorn, K.S., Anatomy of hot spots in protein interfaces, Journal of Molecular Biology, 280, 1–9, 1998.
22. Higueruelo, A.P., Schreyer, A., Bickerton, G.R.J., Pitt, W.R., Groom, C.R., Blundell, T.L., Atomic Interactions and Profile of Small Molecules Disrupting Protein-Protein Interfaces: the TIMBAL Database, Chemical Biology and Drug Design, 74, 457–467, 2009.
23. Zak, K.M., Kitel, R., Przetocka, S., Golik, P., Guzik, K., Musielak, B., et al., Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1, Structure, 23, 2341–2348, 2015.
24. Sterling, T., Irwin, J.J., ZINC 15-Ligand Discovery for Everyone, Journal of Chemical Information and Modeling, 55, 2324–2337, 2015.
25. Koes, D.R., Camacho, C.J., PocketQuery: protein-protein interaction inhibitor starting points from protein-protein interaction structure, Nucleic Acids Research, 40, W387–W392, 2012.
26. Morris, G.M., Huey, R., Lindstrom, W., Sanner, M.F., Belew, R.K., Goodsell, D.S., et al., AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility, Journal of Computational Chemistry, 30, 2785–2791, 2009.
27. Sousa da Silva, A.W., Vranken, W.F., ACPYPE - AnteChamber PYthon Parser interfacE, BMC Res Notes, 5, 367, 2012.
28. Jakalian, A., Bush, B.L., Jack, D.B., Bayly, C.I., Fast, efficient generation of high-quality atomic Charges. AM1-BCC model: I. Method, Journal of Computational Chemistry, 21, 132–146, 2000.
29. Wang, J., Wolf, R., Caldwell, J., Kollman, P., Case, D., Development and testing of a general amber force field, Journal of Computational Chemistry, 25, 1157–1174, 2004.
30. Pronk, S., Pall, S., Schulz, R., Larsson, P., Bjelkmar, P., Apostolov, R., et al., GROMACS 4.5: a high-throughput and highly parallel open-source molecular simulation toolkit, Bioinformatics, 29, 845–854, 2013.
31. Lindorff-Larsen, K., Piana, S., Palmo, K., Maragakis, P., Klepeis, J.L., Dror, R.O., et al., Improved side-chain torsion potentials for the Amber ff99SB protein force field, Proteins-Structure Function and Bioinformatics, 78, 1950–1958, 2010.
32. Parrinello, M., Rahman, A., Polymorphic Transitions in Single-Crystals - A New Molecular-Dynamics Method, Journal of Applied Physics, 52, 7182–7190, 1981.
33. Nose, S., A Unified Formulation of the Constant Temperature Molecular-Dynamics Methods. Journal of Chemical Physics, 81, 511–519, 1984.
34. Hoover, W.G., Canonical Dynamics - Equilibrium Phase-Space Distributions. Physical Review A, 31, 1695–1697, 1985.
35. Case, D.A., Betz, R.M., Cerutti, D.S., Cheatham, T.E. III, Darden, T.A., Duke, R.E., et al., Amber 18, University of California, San Francisco, 2018.
36. Onufriev, A., Bashford, D., Case, D.A., Modification of the generalized Born model suitable for macromolecules, Journal of Physical Chemistry B, 104, 3712–3720, 2000.
37. Onufriev, A., Bashford, D., Case, D.A., Exploring protein native states and large-scale conformational changes with a modified generalized born model, Proteins-Structure Function and Bioinformatics, 55, 383– 394, 2004.
38. Weiser, J., Shenkin, P.S., Still, W.C., Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO), Journal of Computational Chemistry, 20, 217–230, 1999.
39. Zak, K.M., Grudnik, P., Guzik, K., Zieba, B.J., Musielak, B., Dömling, A., et al., Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1), Oncotarget, 7, 30323–30335, 2016.
40. Sun, C., Cheng, Y., Dong, J., Hu, L., Zhang, Y., Shen, H., et al., Novel PD-L1/VISTA Dual Inhibitor as Potential Immunotherapy Agents, Journal of Medicinal Chemistry, 68, 156–173, 2025.
41. Sasikumar, P.G., Sudarshan, N.S., Adurthi, S., Ramachandra, R.K., Samiulla, D.S., Lakshminarasimhan, A., et al., PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy, Communications Biology, 4, 699, 2021.
42. Zyla, E., Musielak, B., Holak, T.A., Dubin, G., Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis, Molecules, 26, 4848, 2021.
43. Laskowski, R.A., Swindells, M.B., LigPlot+: multiple ligand-protein interaction diagrams for drug discovery, Journal of Chemical Information and Modeling, 51, 2778-86, 2011.
44. Cukuroglu, E., Gursoy, A., Keskin, O., HotRegion: a database of predicted hot spot clusters, Nucleic Acids Research, 40, D829–D833, 2012.
45. Lim, H., Chun, J., Jin, X., Kim, J., Yoon, J., No, K.T., Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method, Scientific Reports, 9, 16727, 2019.
46. Wu, Q., Jiang, L., Li, S.C., He, Q.J., Yang, B., Cao, J., Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway, Acta Pharmacologica Sinica, 42, 1–9, 2021.
47. Musielak, B., Kocik, J., Skalniak, L., Magiera-Mularz, K., Sala, D., Czub, M., et al., CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not ?, Molecules, 24, 2804, 2019.
48. Alibay, I., Magarkar, A., Seeliger, D., Biggin, P.C., Evaluating the use of absolute binding free energy in the fragment optimisation process, Communications Chemistry, 5, 105, 2022.